Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?

Area of Science:

• Neurology
• Pharmacology
• Clinical Medicine

Background:

• Huntington's disease (HD) management relies heavily on clinical experience due to limited empirical evidence.
• Current treatment options for HD symptoms are restricted, with few approved medications.
• Evidence-based medicine principles are challenging to apply in HD due to data scarcity.

Purpose of the Study:

• To review the available evidence and expert opinion on medical treatments for Huntington's disease.
• To discuss therapeutic strategies for the motor, psychiatric, and cognitive features of HD.
• To highlight the limitations of current treatments and the need for further research.

Main Methods:

• Literature review of existing studies on HD treatments.
• Analysis of current expert opinions and clinical guidelines.
• Discussion of pharmacological options for chorea, psychiatric disturbances, and cognitive dysfunction.

Main Results:

• Tetrabenazine is the only approved medication for chorea in HD, but has limitations.
• Multipurpose antipsychotics are frequently used for chorea when tetrabenazine is contraindicated.
• Selective serotonin reuptake inhibitors (SSRIs) and mood stabilizers are used for psychiatric symptoms, lacking strong empirical support.
• No effective treatments are currently available for cognitive dysfunction in HD.

Conclusions:

• Therapeutic decisions in HD are often based on limited evidence and expert consensus.
• Current pharmacological options address some symptoms but have significant limitations.
• There is a critical need for more robust clinical trials to guide HD treatment strategies, particularly for cognitive impairment.